MPSYF News and Press, Morphosys Ag Ord From 10/25/23

Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million) Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65% Anticipate full year 2023 Monjuvi U.S. net product sales to be US$ 85-95 million and full year gross margin ...

Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company's third clinical program to receive Fast Track designation PLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 12, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the U.S. Food and Drug Administrati...

2023-08-10 11:40:10 ET MorphoSys AG (MOR) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Julia Neugebauer – Head of Investor Relations Jean-Paul Kress – Chief Executive Officer Tim Demuth – Chief Research and...

2023-05-22 11:17:03 ET Summary Sales beat: Despite Monjuvi's setbacks, MorphoSys exceeds Q1 2023 sales expectations with €62.3m and robust 11% YoY US growth. Pelabresib Potential: Accelerated MANIFEST-2 Pelabresib data readout could be a key catalyst, promising MF candidate...

2023-05-06 03:08:07 ET MorphoSys AG (MOR) Q1 2023 Earnings Conference Call May 04, 2023, 8:00 AM ET Company Participants Julia Neugebauer - Vice President, Head of Investor Relations Jean-Paul Kress - Chief Executive Officer Tim Demuth - Chief Research and Develo...

Conference Call Alert MUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on Ma...

2023-03-16 11:11:16 ET The following slide deck was published by MorphoSys AG in conjunction with their 2022 Q4 earnings call. For further details see: MorphoSys AG 2022 Q4 - Results - Earnings Call Presentation

2023-03-16 11:10:09 ET MorphoSys AG (MOR) Q4 2022 Earnings Conference Call March 16, 2023, 8:00 AM ET Company Participants Julia Neugebauer - Head of Investor Relations Jean-Paul Kress - Chief Executive Officer Tim Demuth - Chief Research and Development Officer ...

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 9, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT). MorphoSys' Management team will host a conference call and...

MUNICH, GERMANY / ACCESSWIRE / March 2, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure. While the data from these pre-clinical programs are promising, MorphoSys would ne...